We observed a significantly lower expression of BECLIN1 in both AML and ALL patients compared to the control group, which was similar to the findings of Sara M. Radwan et al. They also reported reduced BECLIN1 expression in AML (30 cases) and ALL (25 cases) patients (25). Here, BECN1 is linked to acute lymphoblastic leukemia.